First National Bank & Trust Co. of Newtown Sells 170 Shares of Johnson & Johnson (NYSE:JNJ)

First National Bank & Trust Co. of Newtown reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,693 shares of the company’s stock after selling 170 shares during the quarter. Johnson & Johnson makes up about 1.2% of First National Bank & Trust Co. of Newtown’s portfolio, making the stock its 14th biggest holding. First National Bank & Trust Co. of Newtown’s holdings in Johnson & Johnson were worth $6,433,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Verity Asset Management Inc. boosted its stake in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Verity Asset Management Inc. now owns 9,882 shares of the company’s stock worth $1,601,000 after acquiring an additional 3,654 shares during the period. Lewis Asset Management LLC boosted its stake in Johnson & Johnson by 7.5% in the 3rd quarter. Lewis Asset Management LLC now owns 4,607 shares of the company’s stock valued at $747,000 after purchasing an additional 323 shares during the period. Hudson Value Partners LLC boosted its stake in Johnson & Johnson by 3.1% in the 3rd quarter. Hudson Value Partners LLC now owns 40,381 shares of the company’s stock valued at $6,544,000 after purchasing an additional 1,217 shares during the period. LS Investment Advisors LLC boosted its stake in Johnson & Johnson by 2.3% in the 3rd quarter. LS Investment Advisors LLC now owns 15,742 shares of the company’s stock valued at $2,551,000 after purchasing an additional 353 shares during the period. Finally, Trinity Legacy Partners LLC boosted its stake in Johnson & Johnson by 11.9% in the 3rd quarter. Trinity Legacy Partners LLC now owns 35,375 shares of the company’s stock valued at $5,717,000 after purchasing an additional 3,759 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JNJ. Citigroup boosted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. The Goldman Sachs Group reduced their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Wells Fargo & Company lifted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $175.00.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $155.62 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The stock has a market capitalization of $374.67 billion, a P/E ratio of 22.52, a price-to-earnings-growth ratio of 2.80 and a beta of 0.53. The stock has a fifty day moving average of $162.61 and a 200-day moving average of $155.81.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the prior year, the firm earned $2.66 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.19%. Johnson & Johnson’s payout ratio is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.